ARCHIVES

Drug Development: Tivozanib Trial Discontinued Due to Insufficient Enrollment

This article is from The Cancer Letter archive.

Vol. 40 No. 06 | February 7, 2014

Download PDF Visit The Full Archive

Related Articles

Murray Copeland Display Dedicated

March 18, 1983

Educational Strategies On Mammography, Not Guidelines, To Come From NCAB

February 28, 1997

Cooperative Groups Start To Deploy Medidata Rave, Despite Contract Dispute

April 22, 2011

New NCI Division Wins Approval To Fund Grants In Basic Biobehavioral Research

April 17, 1998

Cancer Groups Criticize FDA For Ignoring Expert Advice.

November 24, 2000

In Brief: Von Hoff to Direct Arizona Cancer Center; American Health Foundation Appoints Nixon

April 23, 1999